Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

Evotec Partners with Bristol Myers Squibb

Friday, March 17, 2023

Evotec announced progress within the Company’s strategic partnership with Bristol Myers Squibb relating to building a molecular glue-based pipeline.

Evotec and Bristol Myers Squibb entered into strategic protein degradation partnership in 2018 and expanded it in May of 2022, because of the highly productive initial collaboration generating a promising pipeline. The partnership continues to build a leading pipeline of novel molecular glue degraders, targeting high-value targets in the field of oncology and beyond.

This strategic alliance is to discover and develop a leading pipeline of molecular glue degraders for a range of therapeutic indications leveraging all of Evotec’s proprietary PanOmics and PanHunter platforms as well as A.I./M.L.-based drug discovery and development capabilities.

The extension and expansion of partnership with BMS continues to deliver high value programmes. The Omics-based, highly systematic, and industrialised approach to identify very promising molecular glues continually exceeds all expectations and will translate into an extraordinary pipeline of first-in-class product opportunities.

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024